INS and obesity due to melanocortin 4 receptor deficiency: Obesity and greater body fat volume have been considered one of the primary adverse effects of insulin therapy in both Type 1 and 2 diabetes.[26,27] In the Diabetes Control and Complications Trial, whereas waist to hip ratios did not differ, T1DM patients receiving intensive insulin therapy significantly gained body weight compare to patients receiving conventional therapy.